# US 2013/0158019 A1 · Pyrimidine compounds that inhibit anaplastic lymphoma kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158019 A1
- Document ID: US20130158019A1
- Status: Published application
- Kind: A1
- Application number: 13/697,730
- Filed: 2011-05-04
- Published: 2013-06-20
- Earliest claimed: 2010-05-11
- Assignees: Amgen Inc.
- Inventors: Marian C. Bryan; Alan C. Cheng; Elizabeth M. Doherty; James R. Falsey; Ingrid M. Fellows; Joseph L. Kim; Richard T. Lewis; Michele H. Potashman; Douglas A. Whittington
- Web page: https://patentgrep.com/patent/US20130158019A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a pharmaceutically acceptable salt of the stereoisomer, or a mixture thereof,
wherein:
X is selected from —CH2—, —N(H)—, —O—, or —S—;
V is absent or is selected from —CH2—, —O—, —S—, or —NH—; wherein if V is —O—, —S—, or —NH—, then r is 1 and q is 1;
the subscript p is selected from 0, 1, 2, or 3, wherein X is CH2 if p is 0;
the subscript q is selected from 0 or 1;
the subscript r is selected from 0 or 1:
the symbol indicates that the bond can be a single or double bond;
Z is a C6-C10 aryl or a 5-10 membered heteroaryl comprising 1, 2, 3, or 4 heteroatoms independently selected from O, S, or N, wherein the C6-C10 aryl or the 5-10 membered heteroaryl are unsubstituted or are optionally substituted with 1, 2, 3, or 4 substituents independently selected from —Z′, —O—Z′, —S—Z′, —NH—Z′, —CH2Z′, —F, —Cl, —Br, —I, —C≡N, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C1-C4)alkylene-OH, —NH2, —NH((C1-C4)alkyl), —N((C1-C4)alkyl)2, —C(═O)NH2, —C(═O)NH((C1-C4)alkyl), —C(═O)N((C1-C4)alkyl)2, —C(═O)NH—Z′, —SO2NH2, —SO2NH((C1-C4)alkyl), —SO2N((C1-C4)alkyl)2, —SO2NH—Z′, —NHSO2—(C1-C4)alkyl, —NHSO2—Z′, —NHC(═O)—(C1-C4)alkyl, —NHC(═O)—Z′, —SO2—(C1-C4)alkyl, —SO2—Z′, —SO—(C1-C4)alkyl, —(C1-C4)alkylene-NH—C(═O)—(C1-C4)alkyl, —CF3, —C(═O)—(C1-C4)alkyl, —CO2H, —C(═O)—Z′, —C(═O)—O—(C1-C4)alkyl, —C(═O)NH—(C1-C4)alkylene-NH2, —C(═O)NH—(C1-C4)alkylene-NH((C1-C4)alkyl), —C(═O)NH—(C1-C4)alkylene-N((C1-C4)alkyl)2, —(C1-C4)alkylene-C(═O)—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—O—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—OH, —OH, —O—(C1-C6)alkyl, —SH, —S—(C1-C6)alkyl, —OCF3, or —OCHF2; and two adjacent substituents on the C6-C10 aryl or the 5-10 membered heteroaryl may join to form a 5 or 6 membered ring comprising 0, 1, or 2 heteroatoms selected from O, N, or S; and further wherein the C6-C10 aryl and the 5-10 membered heteroaryl may be monocyclic or bicyclic and further wherein both rings of a bicyclic C6-C10 aryl or a bicyclic 5-10 membered heteroaryl may be aromatic or one of the rings may be partially saturated and the other ring may be aromatic and either the partially saturated ring or the aromatic ring may be bonded to V, if present, or to the C atom bearing Rb and Rb′ if V is not present, or to the C atom bearing Ra and Ra′ if V is not present and q is 0, or to the N atom bonded to the C(═O) if V is not present, q is 0, and r is 0; and further wherein, the partially saturated ring of a bicyclic C6-C10 aryl or a bicyclic 5-10 membered heteroaryl may include a —C(═O)— ring member;
Z′ is a C6-C10 aryl, a 5-10 membered heteroaryl comprising 1, 2, 3, or 4 heteroatoms independently selected from O, S, or N, or a 5-7 membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from O, S, or N, wherein the C6-C10 aryl, the 5-10 membered heteroaryl, or the 5-7 membered heterocyclyl are unsubstituted or are optionally substituted with 1 or 2 substituents independently selected from —F, —Cl, —Br, —I, —C≡N, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C1-C4)alkylene-OH, —NH2, —NH((C1-C4)alkyl), —N((C1-C4)alkyl)2, —C(═O)NH2, —C(═O)NH((C1-C4)alkyl), —C(═O)N((C1-C4)alkyl)2, —SO2NH2, —SO2NH((C1-C4)alkyl), —SO2N((C1-C4)alkyl)2, —NHSO2—(C1-C4)alkyl, —NHC(═O)—(C1-C4)alkyl, —SO2—(C1-C4)alkyl, —SO—(C1-C4)alkyl, —(C1-C4)alkylene-NH—C(═O)—(C1-C4)alkyl, —CF3, —C(═O)—(C1-C4)alkyl, —CO2H, —C(═O)—O—(C1-C4)alkyl, —C(═O)NH—(C1-C4)alkylene-NH2, —C(═O)NH—(C1-C4)alkylene-NH((C1-C4)alkyl), —C(═O)NH—(C1-C4)alkylene-N((C1-C4)alkyl)2, —(C1-C4)alkylene-C(═O)—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—O—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—OH, —OH, —O—(C1-C6)alkyl, —SH, —S—(C1-C6)alkyl, —OCF3, or —OCHF2;
Ra and Ra′ are absent if r is 0 or are independently selected from —H, —(C1-C6)alkyl, —C≡N, —OH, or —CF3; or Ra and Ra′ may together represent a ═O; or Ra and Ra′ may join together with the carbon atom to which they are attached to form a cycloalkyl ring having from 3 to 6 members;
Rb and Rb′ are absent if q is 0 or are independently selected from —H, —(C1-C6)alkyl, —C≡N, —OH, or —CF3; or Rb and Rb′ may together represent a ═O; or Rb and Rb′ may join together with the carbon atom to which they are attached to form a cycloalkyl ring having from 3 to 6 members;
Rc is selected from —H, —(C1-C6)alkyl, —CF3, —F, —Cl, —Br, or —I;
Rd is selected from —H, —(C1-C6)alkyl, —CF3, —F, —Cl, —Br, or —I;
Re and Re′ are independently selected from —H or —(C1-C6)alkyl;
W is a C6-C10 aryl, a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S, or N, or a 5-7 membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from O, S, or N, wherein the C6-C10 aryl, the 5-10 membered heteroaryl, or the 5-7 membered heterocyclyl are unsubstituted or are optionally substituted with 1, 2, 3, or 4 substituents independently selected from —W′, —O—W′, —S—W′, —CH2—W′, —N(H)—W′, —O—CH2-W′, —C(═O)—W′, —C(═O)NH—W′, —SO2NH—W′, —NHSO2—W′, —NHC(═O)—W′, —SO2—W′, —F, —Cl, —Br, —I, —C≡N, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C1-C4)alkylene-OH, —NH2, —NH((C1-C4)alkyl), —N((C1-C4)alkyl)2, —C(═O)NH2, —C(═O)NH((C1-C4)alkyl), —C(═O)N((C1-C4)alkyl)2, —SO2NH2, —SO2NH((C1-C4)alkyl), —SO2N((C1-C4)alkyl)2, —NHSO2—(C1-C4)alkyl, —NHC(═O)—(C1-C4)alkyl, —SO2—(C1-C4)alkyl, —SO—(C1-C4)alkyl, —(C1-C4)alkylene-NH—C(═O)—(C1-C4)alkyl, —CF3, —C(═O)—(C1-C4)alkyl, —CO2H, —C(═O)—O—(C1-C4)alkyl, —C(═O)NH—(C1-C4)alkylene-NH2, —C(═O)NH—(C1-C4)alkylene-NH((C1-C4)alkyl), —C(═O)NH—(C1-C4)alkylene-N((C1-C4)alkyl)2, —(C1-C4)alkylene-C(═O)—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—O—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—OH, —OH, —O—(C1-C6)alkyl, —SH, —S—(C1-C6)alkyl, —OCF3, or —OCHF2; and two adjacent substituents on the C6-C10 aryl or the 5-10 membered heteroaryl may join to form a 5 or 6 membered ring comprising 0, 1, or 2 heteroatoms selected from O, N, or S; and further wherein the C6-C10 aryl and the 5-10 membered heteroaryl may be monocyclic or bicyclic and further wherein both rings of a bicyclic C6-C10 aryl or a bicyclic 5-10 membered heteroaryl may be aromatic or one of the rings may be partially saturated and the other ring may be aromatic and either the partially saturated ring or the aromatic ring may be bonded to the N atom to which W is attached; and further wherein, the partially saturated ring of a bicyclic C6-C10 aryl or a bicyclic 5-10 membered heteroaryl may include a —C(═O)— ring member and the 5-7 membered heterocyclyl group may include a —C(═O)— ring member; and
W′ is a C6-C10 aryl, a 5-10 membered heteroaryl comprising 1, 2, 3, or 4 heteroatoms independently selected from O, S, or N, or a 5-7 membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from O, S, or N, wherein the C6-C10 aryl, the 5-10 membered heteroaryl, or the 5-7 membered heterocyclyl are unsubstituted or are optionally substituted with 1 or 2 substituents independently selected from —F, —Cl, —Br, —I, —C≡N, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C1-C4)alkylene-OH, —NH2, —NH((C1-C4)alkyl), —N((C1-C4)alkyl)2, —C(═O)NH2, —C(═O)NH((C1-C4)alkyl), —C(═O)N((C1-C4)alkyl)2, —SO2NH2, —SO2NH((C1-C4)alkyl), —SO2N((C1-C4)alkyl)2, —NHSO2—(C1-C4)alkyl, —NHC(═O)—(C1-C4)alkyl, —SO2—(C1-C4)alkyl, —SO—(C1-C4)alkyl, —(C1-C4)alkylene-NH—C(═O)—(C1-C4)alkyl, —CF3, —C(═O)—(C1-C4)alkyl, —CO2H, —C(═O)—O—(C1-C4)alkyl, —C(═O)NH—(C1-C4)alkylene-NH2, —C(═O)NH—(C1-C4)alkylene-NH((C1-C4)alkyl), —C(═O)NH—(C1-C4)alkylene-N((C1-C4)alkyl)2, —(C1-C4)alkylene-C(═O)—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—O—(C1-C4)alkyl, —(C1-C4)alkylene-C(═O)—OH, —OH, —O—(C1-C6)alkyl, —SH, —S—(C1-C6)alkyl, —OCF3, or —OCHF2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein p is 2.

### Claim 3 (depends on 1)

The compound of claim 1, wherein r is 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein V is absent.

### Claim 5 (depends on 1)

The compound of claim 1, wherein V is —O—.

### Claim 6 (depends on 1)

The compound of claim 1, wherein V is —CH2—.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is —CH2—.

### Claim 8 (depends on 1)

The compound of claim 1, wherein X is —O—.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X is —S—.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X is —N(H)—.

### Claim 11 (depends on 1)

The compound of claim 1, wherein q is 0.

### Claim 12 (depends on 1)

The compound of claim 1, wherein q is 1 and Rb and Rb′ are independently selected from —H, —CH3, or Rb and Rb′, when taken together, represent a ═O.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is a compound of Formula II:
or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a pharmaceutically acceptable salt of the stereoisomer, or a mixture thereof, wherein the symbol indicates that the chiral carbon atom to which the is attached may have the R stereochemistry, the S stereochemistry, or may be a mixture of compounds with the R and S stereochemistry wherein the mixture may be racemic, or the mixture may include a greater amount of compounds with the R stereochemistry compared to the amount of compounds with the S stereochemistry, or the mixture may include a greater amount of compounds with the S stereochemistry compared to the amount of compounds with the R stereochemistry.

### Claim 14 (depends on 13)

The compound of claim 13, wherein the compound of Formula II is a compound of Formula IIA:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the compound of Formula II is a compound of Formula IIB:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 13)

The compound of claim 13, wherein Re and Re′ are independently selected from —H or —CH3.

### Claim 17 (depends on 16)

The compound of claim 16, wherein Re and Re′ are both —H.

### Claim 18 (depends on 13)

The compound of claim 13, wherein Ra and Ra′ are independently selected from —H or —CH3.

### Claim 19 (depends on 18)

The compound of claim 18, wherein Ra and Ra′ are both —H.

### Claim 20 (depends on 13)

The compound of claim 13, wherein Rc is selected from —H or —CH3.

### Claim 21 (depends on 20)

The compound of claim 20, wherein Rc is —H.

### Claim 22 (depends on 13)

The compound of claim 13, wherein Rd is selected from —H or —CH3.

### Claim 23 (depends on 22)

The compound of claim 22, wherein Rd is —H

### Claim 24 (depends on 1)

The compound of claim 1, wherein r is 0.

### Claim 25 (depends on 24)

The compound of claim 24, wherein q is 0.

### Claim 26 (depends on 1)

The compound of claim 1, wherein Z is an unsubstituted or substituted phenyl, pyridyl, pyrimidinyl, naphthyl, indanyl, 2,3-dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, indolyl, thiazolyl, imidazolyl, imidazo[1,2-a]pyridyl, quinolinyl, isoquinolinyl, 1,2,3,4,4a,8a-hexahydroquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, pyridazinyl, pyrazinyl, indazolyl, isothiazolyl, or oxazolyl.

### Claim 27 (depends on 1)

The compound of claim 1, wherein Z is an unsubstituted or substituted phenyl, pyridyl, pyrimidinyl, naphthyl, indanyl, 2,3-dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, indolyl, thiazolyl, imidazolyl, imidazo[1,2-a]pyridyl, quinolinyl, isoquinolinyl, 1,2,3,4,4a,8a-hexahydroquinolinyl, or 2,3-dihydrobenzo[b][1,4]dioxinyl.

### Claim 28 (depends on 1)

The compound of claim 1, wherein Z is an unsubstituted or substituted phenyl.

### Claim 29 (depends on 28)

The compound of claim 28, wherein Z is selected from
wherein the symbol when drawn through a bond indicates the point of attachment to the rest of the molecule.

### Claim 30 (depends on 26)

The compound of claim 26, wherein Z is selected from
wherein the symbol when drawn through a bond indicates the point of attachment to the rest of the molecule.

### Claim 31 (depends on 1)

The compound of claim 1, wherein Z is substituted with at least one substituent selected from —Z′ or —OZ′.

### Claim 32 (depends on 31)

The compound of claim 31, wherein Z is phenyl and Z′ is an optionally substituted phenyl.

### Claim 33 (depends on 1)

The compound of claim 1, wherein W is an unsubstituted or substituted phenyl, pyridyl, pyrimidinyl, naphthyl, indanyl, 2,3-dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, indolyl, thiazolyl, imidazolyl, imidazo[1,2-a]pyridyl, isoindolin-1-onyl, indolinyl, pyrazolyl, pyridinonyl, quinolinyl, isoquinolinyl, 1,2,3,4,4a,8a-hexahydroquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, pyridazinyl, pyrazinyl, indazolyl, isothiazolyl, or oxazolyl.

### Claim 34 (depends on 1)

The compound of claim 1, wherein W is an unsubstituted or substituted phenyl, pyridyl, pyrimidinyl, naphthyl, indanyl, 2,3-dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, indolyl, thiazolyl, imidazolyl, imidazo[1,2-a]pyridyl, isoindolin-1-onyl, indolinyl, pyrazolyl, pyridinonyl, quinolinyl, isoquinolinyl, 1,2,3,4,4a,8a-hexahydroquinolinyl, or 2,3-dihydrobenzo[b][1,4]dioxinyl.

### Claim 35 (depends on 1)

The compound of claim 1, wherein W is an unsubstituted or substituted phenyl, pyridyl, indolyl, isoindolin-1-onyl, indolinyl, pyrazolyl, pyridinonyl, quinolinyl, isoquinolinyl, or 2,3-dihydrobenzo[b][1,4]dioxinyl.

### Claim 36 (depends on 1)

The compound claim 1, wherein W is an unsubstituted or substituted phenyl.

### Claim 37 (depends on 1)

The compound of claim 1, wherein W is selected from
wherein the symbol when drawn through a bond indicates the point of attachment to the rest of the molecule.

### Claim 38 (depends on 1)

The compound of claim 1, wherein W is substituted with at least one substituent selected from —W′, —O—W′, —CH2—W′, N(H)—W′, —O—CH2-W′, or —C(═O)—W′.

### Claim 39 (depends on 1)

The compound of claim 1, wherein W is a phenyl substituted with at least one —O—(C1-C6)alkyl group.

### Claim 40 (depends on 1)

The compound of claim 1, wherein the compound is selected from
or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 and at least one pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 42 (depends on 1)

A method of treating cancer, the method comprising:
administering to a subject an effective amount of the compound of claim 1.

### Claim at position 43

43-45. (canceled)

### Claim 46 (depends on 1)

A method of treating a condition where it is desired to inhibit ALK activity, comprising administering to a subject an effective amount of the compound of claim 1.

### Claim at position 45

47-54. (canceled)

### Claim 55 (depends on 41)

A method of treating cancer, the method comprising: administering to a subject an effective amount of the pharmaceutical composition of claim 41.

### Claim 56 (depends on 41)

A method of treating a condition where it is desired to inhibit ALK activity, comprising administering to a subject an effective amount of the pharmaceutical composition of claim 41.
